Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$58.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$46.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bio-Rad Laboratories Inc Acquires Cell Sorting System From Propel Labs
Bio-Rad Laboratories Inc announced that that they have acquired a new cell sorting system from Propel Labs. Under the terms of agreement, Bio-Rad has acquired an automated, easy-to-use benchtop sorting flow cytometer. The instrument will be offered by Bio-Rad as the S3(TM) Cell Sorter. First shipments are anticipated in January 2013. Other terms of the agreement were not disclosed.
Latest Developments for Bio-Rad Laboratories Inc
- Bio-Rad Laboratories Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
- Bio-Rad Laboratories Inc Issues FY 2013 Revenue Guidance Above Analysts' Estimates-Conference Call
- Bio-Rad Laboratories Inc Signs Definitive Agreement to Acquire AbD Serotec from MorphoSys AG
- Bio-Rad Laboratories Inc Lowers FY 2012 Revenue Guidance-Conference Call
Latest Key Developments in Medical
- CryoLife Inc Receives Conditional IDE Approval To Begin Clinical Trials For PerClot In The U.S.
- Essilor International SA Acquires Eight Businesses
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System
- Share this
- Link this
- Digg this
Follow Reuters